薬剤部研究室では、医薬品の有効性・安全性確保と適正使用推進のため、薬物動態学、細胞生物学、疫学（症例対照・コホート）を主な基盤として、以下のような基礎および臨床研究を実施しています。
- 薬物の血中濃度モニタリングと投与設計
- 薬物代謝酵素・薬物トランスポータの分子機構と個別化医療への応用
- 薬効・副作用に関わる変動因子並びにバイオマーカーの検索と有用性評価
- Pharmacokinetics/Pharmacodynamicsに基づく至適投与設計
- 医療における薬剤師の役割と薬剤業務の質的・量的評価
上記研究内容に関連した薬物動態学、分子細胞生物学、薬品分析化学、医療統計学、論文作成の指導を行う。
三重大学大学院医学系研究科 臨床医学系講座 臨床薬剤学分野へのリンク↓
https://www.medic.mie-u.ac.jp/organization/course/cl_pharmacy/
【業績】
論文(2017年度以降)
（2024年度）
1. Kato H, Hagihara M, Asai N, Mikamo H, Iwamoto T. Evaluation of effectiveness, hyperkalaemia, and hepatotoxicity
of trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis jirovecii pneumonia in paediatric patients:
A single-centre retrospective study. Int J Antimicrob Agents. 2024 May;63(5):107151.
2. Shiraishi C, Kotera M, Ota Y, Takeshige E, Minamide C, Kurimoto R, Sato A, Inamori M, Kataoka M, Ogura T,
Tamaru S, Iwamoto T. [Evaluation of Pharmacy Students' Understanding of Clinical Trials and Research through
Questionnaires Before and After the Hospital Practical Training]. Yakugaku Zasshi. 2024;144(5):567-576.
3. Kato H, Hagihara M, Hiramatsu S, Suematsu H, Nishiyama N, Asai N, Mikamo H, Yamamoto K, Iwamoto T.
Evaluating the antimicrobial efficacy of ceftriaxone regimens: 1 g twice daily versus 2g once daily in a murine
model of Streptococcus pneumoniae pneumonia. JAC-Antimicrob. Resist. 2024 Jun 4;6(3):dlae092.
4. Asai Y, Muramatsu A, Kobayashi T, Takasaki I, Murasaka T, Izukawa A, Miyada K, Okazaki T, Yanagawa T,
Abe Y, Takai Y, Iwamoto T. A multicentral prospective cohort trial of a pharmacist-led nutritional intervention
on serum potassium levels in outpatients with chronic kidney disease: The MieYaku-Chronic Kidney Disease
project. PLoS One. 2024 May 31;19(5):e0304479.
5. Kato H, Shiraishi C, Hagihara M, Mikamo H, Iwamoto T. Association between voriconazole-induced visual
hallucination and dopamine in an analysis of the Food and Drug Administration (FDA) Adverse event Reporting
System database. Sci Rep. 2024 May 31;14(1):12519.
6. Asai Y, Arihara H, Omote S, Tanio E, Yamashita S, Higuchi T, Hashimoto E, Yamada M, Tsuji H, Kondo Y,
Hayashi M, Tashiro T, Hayakawa Y, Yamamoto Y, Iwamoto T. A decision tree model for predicting high
mono-N-desethylamiodarone concentrations and reducing tissue toxicity in patients with low dose amiodarone
therapy: a multicentral retrospective cohort study. Int. J. Clin. Pharmacol.Ther. 2024 Sep;62(9):402-411.
7. Iwamoto et al., Lymphocyte activation markers predict the therapeutic response to immune checkpoint
inhibitors: a case-control study. Cancer Med. 2024 June 13(12) e7418
8. Hirai T, Ueda S, Ogura T, Katayama K, Dohi K, Kondo Y, Sakazaki Y, Ishitsuka Y, Iwamoto T. Hyperkalemic
effect of drug–drug interaction between esaxerenone and trimethoprim in patients with hypertension: a pilot study.
J Pharm Health Care Sci. 2024 Aug 2;10(1):46.
9. Shiraishi C, Kato H, Ogura T, Iwamoto T. An investigation of broad-spectrum antibiotic–induced liver injury
based on the FDA Adverse Event Reporting System and retrospective observational study. Sci Rep.
2024 Aug 6;14(1):18221.
10. Shiraishi C, Kato H, Ogura T, Iwamoto T. Association between age and onset of daptomycin-induced adverse
events using the U.S. Food and Drug Administration Adverse Event Reporting System. J Infect Chemother.
2024 Aug 27:S1341-321X(24)00233-2.
11. Hirai T, Mori Y, Ogura T, Kondo Y, Sakazaki Y, Ishitsuka Y, Sudo A, Iwamoto T. Influence of loop diuretics on
denosumab-induced hypocalcaemia in osteoporosis: A retrospective observational analysis. J Pharm Health Care Sci.
2024 Sep 27;10(1):60.
12. Asai Y, Takai Y, Kato H, Hiramatsu S, Miki Y, Masuda N, Iwamoto T. A decision tree approach for investigating the
background of research activity of community and hospital pharmacists in Mie Prefecture: a retrospective
questionnaires-based survey. J Pharm Health Care Sci. 2024 Oct 17;10(1):64.
13. Nakagawa Y, Kato H, Iwamoto T. A qualitative study on the current status and problems of pharmacists in home
healthcare from the viewpoint of care managers in medically underpopulated areas in Japan. J Pharm Health Care Sci.
2024 Nov 8;10(1):71.
14. Asai Y, Nakano Y, Yanagawa T, Takahashi M, Iwamoto T. Impact of a Collaborative Pharmacist-Cardiovascular
Surgeon Protocol for High-Risk of Postoperative Delirium on Benzodiazepine Prescription Trends in Hospitalized Patients.
Biol. Pharm. Bull. Accepted.
15. Asai Y, Kato H, Tawara I, Nakano Y, Iwamoto T. Potential of albumin-bilirubin score for estimating the
voriconazole-induced hepatotoxicity undergoing therapeutic drug monitoring: a single-center retrospective cohort
study. Clin Ther. 2025 Jan 30: S0149-2918(25)00006-2.
16. Ooi H, Asai Y et al., The albumin-bilirubin–fibrosis-4 score for predicting teicoplanin-induced abnormal liver
enzyme levels in patients undergoing therapeutic drug monitoring: a multicentral retrospective cohort study.
Ann. Pharmacother. 2025 Mar 12:10600280251319519. doi: 10.1177/10600280251319519.
17. Shiraishi C et al., Changes in the blood cyclosporine level after switching from voriconazole to isavuconazole in
a patient with aplastic anemia: Insights from physiologically based pharmacokinetic model simulation and
the Adverse Event Reporting System database study. Frontiers in Microbiology 2025 Feb 24;16:1525991.
doi: 10.3389/fmicb.2025.1525991.
18. Kato H, Hagihara M, Asai N, Mikamo H, Iwamoto T. A Retrospective Study Comparing the Effectiveness of
Carbapenems and Tazobactam/Piperacillin as an Empirical Treatment for Patients Infected with Bacteroides fragilis.
Anaerobe. 2025 Apr;92:102950. doi: 10.1016/j.anaerobe.2025.102950.
（2023年度）
1. Kato H, Morikawa Y, Hagihara M, Mikamo H, Iwamoto T. Investigation of in-line filter replacement intervals for infusion. J Hosp Infect. 2023 Apr;134:147-152.
2. Nakagawa Y, Kato H, Iwamoto T. An Investigation of antimicrobial therapy for aspiration pneumonia in elderly nursing homes: a retrospective observational study in Japan. Pharmacy Practice 2023 Accept.
3. Kato H, Hagihara M, Asai N, Umemura T, Hirai J, Mori N, Yamagishi Y, Iwamoto T, Mikamo H. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsisinduced disseminated intravascular coagulation - a meta-analysis. Thrombosis Research. 2023 Jun;226:165-172.
4. 中川裕司, 小西友美, 山本高範, 小林竜也, 佐藤賛治, 加藤秀雄, 岩本卓也 三重県下の保 険薬局における小児在宅医療の受け入れに関する実態調査 2023 小児臨床薬理学会雑誌 採択
5. Kato H, Hagihara M, Asai N, Umemura T, Hirai J, Mori N, Yamagishi Y, Iwamoto T, Mikamo H. A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections. Mycoses. 2023 Sep;66(9):815-824.
6. Shiraishi C, Hirai T, Kaneda M, Okamoto A, Kato H, Tanaka K, Kondo E, Ikeda T, Iwamoto T. Factors for the development of anemia in patients with newly introduced olaparib: a retrospective case–control study. Medicine 2023 Jul 28;102(30):e34123.
7. Kato H, Hagihara M, Asai N, Umemura T, Hirai J, Yamagishi Y, Iwamoto T, Mikamo H. Comparison of microbial detection rates in microbial culture methods versus next-generation sequencing in patients with prosthetic joint infection: A systematic review and meta-analysis. J Orthop Surg Res. 2023; Accepted.
8. Shinogi Y, Hirai T, Ishibashi M, Ino K, Tawara I, Iwamoto T. Drug interactions of tacrolimus with letermovir and azole antifungals following hematopoietic stem cell transplantation: A retrospective observational analysis. Pharmacol. Res. Perspect. 2023 Aug;11(4):e01120.
9. Hirai T, Murata T, Tanemura A, Mizuno S, Iwamoto T. Safe co-administration of amenamevir with calcineurin inhibitors: case reports. BPB Reports 2023 Accepted.
10. 田坂健，平松駿一，斉藤慶師，杉野友紀，濱口直美，岡本明大，向原里佳，岩本卓也 「医薬品 トレーサビリティシステム（キュービックス®）を利用した高額医薬品管理の有用性評価」医療 薬学 49(9)347-354(2023)
11. Hirai T, Kondo Y, Sakazaki Y, Seki A, Ishitsuka Y, Iwamoto T. Drug-Drug Interaction Signals between Loop Diuretics and Teicoplanin during Acute Kidney Injury Evaluated using Japanese Spontaneous Adverse Drug Event Reports. Sci Rep 2023 Accepted
12. Asai Y, Konishi T, Yamamoto T, Chikazawa K, Nakano M, Kinoshita E, Yamada K, Ibata H. Impact of antimicrobial
stewardship program-driven educational intervention for vancomycin loading dose on mortality. J. Infect. Chemother.
2023; 29: 1023-1032.
13. Shiraishi C, Kato H, Hagihara M, Asai N, Iwamoto T, Mikamo H. Comparison of clinical efficacy and safety of
baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and
meta-analysis. J Infect Chemother. 2023 Oct 20:S1341-321X(23)00262-3.
14. Takakura A, Hirai T, Hamaguchi N, Mukohara R, Matsumoto K, Yano Y, Iwamoto T. Reduced blood glucose
levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving
mitiglinide and sitagliptin: a case report. J Pharm Health Care Sci. 2023 Dec 11;9(1):46.
15. Hirai T, Aoyama T, Tsuji Y, Itoh T, Matsumoto Y, Iwamoto T. Kinetic-pharmacodynamic model of warfarin for
prothrombin time- international normalized ratio in Japanese patients. Br. J. Clin. Pharmacol. 2023 Nov 12.
doi: 10.1111/bcp.15967.
16. Kato H, Umemura T, Hagihara M, Shiota A, Asai N, Hamada Y, Mikamo H, Iwamoto T. Development of a
therapeutic drug monitoring algorithm for outpatients receiving voriconazole: a multicenter retrospective study.
Br. J. Clin. Pharmacol. 2024 Feb 6. doi: 10.1111/bcp.16004. Online ahead of print.
17. 森川祥彦、家城洋平、田坂健、寺村文恵、岸和田昌之、岩本卓也．病院職員を対象に実施した津波被災後の登院可否に関する
アンケート調査結果 Japanese Journal of Disaster Medicine 2024 29(1):39-45
18. 白石ちひろ，小寺真由美，太田康之，武重榮子，南出ちさと，栗本理恵，佐藤亜紀，稲守美保，片岡美沙紀，小椋透，田丸智巳､
岩本 卓也．病院実務 実習前後に実施したアンケート調査による薬学生の治験及び臨床試験に対する理解の評価
YAKUGAKU ZASSHI アクセプト
19. Asai Y, Takai Y, Murasaka T, Miyake T, Nakamura T, Morikawa Y, Nakagawa Y, Kanayama T, Abe Y, Masuda N,
Takamura Y, Miki Y, Iwamoto T. Evaluation of a joint workshop on study design for hospital and community pharmacists:
a retrospective cross-sectional survey. J Pharm Health Care Sci. 2024 Mar 4;10(1):14.
20. 加藤秀雄，萩原真生，三鴨廣繁，岩本卓也．フィダキソマイシンとの同時簡易懸濁によるClostridium butyricum含有製剤への影響
日本嫌気性菌 感染症学会雑誌 Vol.54 No.2 2024 71-77
（2022年度）
1. 赤阪未来, 平井利典, 吉田健太, 他. 医師，薬剤師に対する女性がん患者への晩期合併症のフォローアップに関する実態調査 日本病院薬剤師会雑誌 2022 Jul;58(7):781-787.
2. Hirai T, Kasai H, Takahashi M et al. Population Pharmacokinetic Model of Amiodarone and N-Desethylamiodarone Focusing on Glucocorticoid and Inflammation. Biol Pharm Bull. 2022;45(7):948-954.
3. Hirai T, Mizuta A, Sasaki T et al. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient. Int J Clin Pharmacol Ther. 2022 Oct;60(10):439-444.
4. Kato H, Hagihara M, Morikawa Y et al. Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia. Antibiotics (Basel). 2022 Jul 22;11(8):983.
5. Kato H, Hagihara M, Asai N et al. Efficacy of Trimethoprim-Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2022 May 26;11(6):719.
6. Kato H, Hagihara M, Kato M et al. A Retrospective Study on the Effectiveness and Safety of Vancomycin versus Daptomycin in Hemodialysis Patients. Antibiotics (Basel). 2022 May 25;11(6):710.
7. Hirai T, Ino K, Ikejiri M et al. Dual Inhibition of CYP3A4 by Voriconazole and Clarithromycin Influences Tacrolimus Pharmacokinetics: Case Series Study. Eur J Drug Metab Pharmacokinet. 2022 Nov;47(6):889-893.
8. Murasaka T, Kato H, Sudo H et al. Usefulness of a Drug Information Resources Website (SAGASU-DI) Created Based on Inquiries to Clinical Pharmacists. Healthcare (Basel). 2022 Aug 14;10(8):1541.
9. Hirai T, Shiraishi C, Ushiro M et al. Population kinetic-pharmacodynamic analysis of serum potassium in patients receiving sulfamethoxazole/trimethoprim. Basic Clin Pharmacol Toxicol. 2022 Nov;13(5):380-391.
10. Kato H, Hagihara M, Asai N et al. A systematic review and meta-analysis of decontamination methods to prevent hospital environmental contamination and transmission of Clostridioides difficile. Anaerobe. 2022 Feb;73:102478
11. Hirai T, Shinogi Y, Ikejiri M et al. Evaluation of bleeding and anticoagulation markers by edoxaban and low-dose cyclosporine: A case series study. Biopharm Drug Dispos. 2022 Oct;43(5):192-200.
12. Shiraishi C, Hirai T, Fujita S et al. Variations in prothrombin time-international normalized ratio caused by drug-drug interaction in patients receiving warfarin: a retrospective observational observational study. Int J Clin Pharm Ther. Accepted.
13. Iwamoto T, Nishikawa K. Monitoring of blood immunosuppressant concentrations and lymphocyte activation for predicting viral infections following kidney transplantation: A pilot study. Medicine Accepted.
14. 岡本明大，岩本卓也「薬剤師の視点から考える慢性疼痛患者の薬物療法」日本慢性疼痛学会機関誌 2022 41:１, 35-39.
15. Akasaka M, Hirai T, Yoshida K et al. Association between cumulative cisplatin dose and reproductive and sexual functions in patients with malignant ovarian germ cell tumors treated with bleomycin, etoposide, and cisplatin therapy. J Pharm Health Care Sci. 2022 Nov 17;8(1):33.
16. Kato H, Hagihara M, Matsuda H et al. Gentamicin pharmacokinetics and optimal dosage in infant patients: a case report and literature review. Int J Environ Res Public Health. 2022 Nov 21;19(22):153600
17. 上林里絵, 池村健治，若井恵里, 杉本浩子, 平井利典, 加藤秀雄, 向原里佳, 石倉健, 今井寛, 岩本卓也 集中治療室の専任薬剤師による注射処方発行前鑑査が薬物治療の適正化に及ぼす効果 日本臨床救急医学会雑誌 アクセプト
18. Shiraishi C, Hirai T, Ogura T, Iwamoto T. Analysis of clinical factors in olaparib-related anemia using adverse drug event reporting databases. Anticancer Res. 2023 Feb;43(2):883-891 19.
19. Hirai T, Ueda S, Ogura T, Katayama K, Dohi K, Hosohata K, Aoyama T, Matsumoto Y, IwamotoT. Hyperkalemia by eplerenone or esaxerenone in the presence or absence of clarithromycin in hypertensive patients: a retrospective observational cohort study. J Hypertens. Accepted.20.
20. Hirai T, Morikawa Y, Onishi R, Nakatani Y, Nishikawa K, Inoue T, Iwamoto T, Impact of glycemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation. Br J Clin Pharmacol. 2023 Jan 14. doi: 10.1111/bcp.15662. Online ahead of print.21.
21. Shiraishi C, Kato H, Imai H, Iwamoto T. Impact of extracorporeal membrane oxygenation in infant treated with vancomycin: a case report. Int. J. Environ. Res. 2023 Accepted.22.
22. Kato H, Morikawa Y, Hagihara M, Mikamo H, Iwamoto T. Investigation of in-line filter replacement intervals for infusion. Journal of Hospital Infection. 2023: S0195-6701
（2021年度）
23. 1. Hirai T, Morikawa Y, Sasaki N et al. Pharmacokinetics of tacrolimus following an overdose in a patient with extreme obesity and genotype CYP3A5*3/*3: a case report. J. Toxicol. Sci. 2022;47(2):71-75.2;47(2):71
2. 岡本明大、岩本卓也 慢性疼痛チーム医療者育成コースにおける学生の教育と今後の薬剤師像 日本慢性疼痛学会機関誌 2021 40:１, 29-36.
3. Hirai T, Hosohata K, Ogawa Y et al. Clinical predictors of nephrotoxicity associated with teicoplanin: meta-analysis and meta-regression. Basic Clin Pharmacol Toxicol. 2022 Jan;130(1):110-121.
4. Aoyama T, Hirai T, Tsuji Y et al. External evaluation of a Bayesian warfarin dose optimization based on a kinetic-pharmacodynamic model. Biol Pharm Bull. 2022;45(1):136-142.
5. 赤阪未来, 前沢忠志, 西岡美喜子, 他. 三重県下のがん診療病院における若年がん患者の妊孕性温存に関する医師、薬剤師、看護師を対象とした意識調査：薬剤師の役割に関する考察 日本病院薬剤師会雑誌 2021 Dec;57(12):1379-1385.
6. Hirai T, Shiraishi C, Murata T et al. Drug-drug interaction between azathioprine and allopurinol in patients with chronic kidney disease: a case series study. BPB Reports 2021; 4(5) 170-174.
7. Hirai T, Hanada K, Iwamoto T et al. Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: a secondary analysis using a retrospective observational data. Basic Clin Pharmacol Toxicol. 2021 Nov;129(5):376-384.
8. Hirai T, Yamaga R, Ishikawa Y et al. Effect of high-dose sulfamethoxazole/trimethoprim and glucocorticoid use on hyperkalemic event: A retrospective observational study. J Infect Chemother. 2021 Nov;27(11):1607-1613.
9. Kato H, Hagihara M, Shibata Y et al. Comparison of mortality between echinocandins and polyenes for an initial treatment of candidemia: a systematic review and meta-analysis. J Infect Chemother. 2021 Jun 30:S1341-321X(21)00178-1.
10. Iqbal J, Iwamoto T. Investigation of biomarkers and handling strategy of erlotinib-induced skin rash in rats. Biol Pharm Bull. 2021;44(8):1050-1059 Editor’s Pickに選出
11. 赤阪未来, 吉田健太, 前沢忠志, 他. 子宮頸癌合併妊娠中に化学療法を施行し、生児の発達を観察した１例, 癌と化学療法 2021 Aug;48(8):1069-1071.
12. Shiraishi C, Matsuda H,Ogura T, et al. Factors affecting serum phenobarbital concentration changes in pediatric patients receiving elixir and powder formulations. J Pharm Health Care Sci.2021 Feb 2;7(1):7
13. Okamoto A, Ikemura K, Mizutani E, et al. Opioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study. J Pharm Health Care Sci. 2021 Feb 1;7(1):3.
14. 森川祥彦, 池村健治, 岩本卓也. 改訂薬学教育モデル・コアカリキュラムにおける災害時医療実習への提言 薬学教育 2021 Jan;4:71-77.
（2020年度）
1. 上林里絵, 川瀬亮介, 岩本卓也. 耳鼻咽喉科領域で使用されるDDS製剤：薬物動態や副作用の特徴 日本耳鼻咽喉科感染症・エアロゾル学会会誌 2020;8(3):180-183.
2. 手島信子, 岩下義明, 荒木美也子, 小田都紀子, 他. 当院栄養サポートチーム介入が栄養療法および栄養指標に与えた影響 日本病態栄養学会誌 2020;23(3):205-213.
3. 若井恵里, 池村健治, 山崎大輔, 他. 高速液体クロマトグラフィー（HPLC）を用いた簡便な血清中ミトタン濃度測定法の開発と臨床応用 TDM研究 2020;37(2-3):77-83.
4. Urano K, Ishibashi M, Matsumoto T, et al. Impact of physician-pharmacist collaborative protocol-based pharmacotherapy management for HIV outpatiens:a retrospective cohort study. J Pharm Health Care Sci. 2020 May 1;6:9.
5. Hiramatsu S, Ikemura K, Fujisawa Y, et al. Concomitant lansaprazole ameliorates cisplatin-induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats. Biopharm Drug Dispos. 2020 Jun;41(6):239-247.
（2019年度）
1. Miyoshi T, Hisamitu T, Ishibasi-Ueda H, Ikemura K et al. Maternal administration of tadalafil improves fetal ventricular systolic function in a Hey2 knockout mouse of fetal heart failure. Int J Cardiol. 2020 Mar 1;302:110-116.
2. Ikemura K, Hiramatsu S, Shinogi Y et al. Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein. Sci Rep. 2019 Dec 30;9(1): 20359.
3. Iwamoto T, Monma F, Ohishi K, et al. Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study. Ther Drug Monit. 2019 Oct;41(5):575-581.
4. Tanaka H, Maki S, Ikemura K et al. Maternal Blood Concentration of Tadalafil and Uterine Blood Flow in Pregnancy. Medicina (Kaunas). 2019 Oct 21;55(10):708.
5. Mizutani H, Hayashi Y, Ikemura K et al. Oxidative DNA Damage and Apoptosis Induced by Aclarubicin,an Anthracycline:Role of Hydrogen Peroxide and Copper. Anticancer Res. 2019 Jul;39(7):3443-3451.
6. 岡本明大, 安積 良紀, 須藤 宏文, 他. 手術部門における麻薬管理業務の電子化による業務効率に関する評価 日本病院薬剤師会雑誌 2019;55(6):658-662.
（2018年度）
1. Wakai E, Ikemura K, Sugimoto H, et al. Risk factors for the development of hypermagnesemia in patients prescribed magnesium oxide: a retrospective cohort study. J Pharm Health Care Sci. 2019 Feb 13;5:4.
2. Tachibana R, Umekawa T, Ikemura K, et al. Tadalafil treatment in mice for preeclampsia with fetal growth restriction has neuro-benefic effects in offspring through modulating prenatal hypoxic conditions. Sci Rep. 2019 Jan 18;9(1):234.
3. 百賢二, 米澤淳, 岩本卓也, 他. 医療現場における薬物相互作用へのかかわり方 実験研究および調査研究事例(総説) 医療薬学 2018.11;44(11):559-567.
4. 木村丈司, 岩本卓也, 大野能之, 他. 医療現場における薬物相互作用へのかかわり方 対応事例・問題点に関するこれまでの報告と特別な背景をもつ患者における薬物相互作用の考え方(総説) 医療薬学 2018.11;44(11):546-558.
5. 大野能之, 樋坂章博, 岩本卓也, 他. 医療現場における薬物相互作用へのかかわり方 新しいガイドラインと医療現場でのマネジメント(総説) 医療薬学 2018.11;44(11):537-545.
6. Mizutani H, Nishimoto A, Ikemura K et al. Oxidative DNA Damage Induced by Pirarubicin, an Anthracycline Anticancer Agent, in the Presence of Copper(II) Anticancer Res. 2018 May;38(5):2643-2648.
7. Hamada Y, Ikemura K, Iwamoto T, et al. Stereoselective Inhibition of Renal Basolateral Human Organic Anion Transporter 3 by Lansoprazole Enantiomers Pharmacology. 2018;101(3-4):176-183.
（2017年度）
1. Ikemura K, Hiramatsu S, Okuda M. Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy Front Pharmacol. 2017 Dec 12;8:911.
2. Murasaka T, Ikemura K, Enokiya T, et al. Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza J Pharm Health Care Sci. 2017 Nov 8;3:26.
3. Mizutani H, Hotta S, Ikemura K, et al. Pirarubicin, an Anthracycline Anticancer Agent, Induces Apoptosis Through Generation of Hydrogen Peroxide Anticancer Res. 2017 Nov;37(11):6063-6069.
4. Yoshikawa K, Umekawa T, Ikemura K et al. Tadalafil Improves L-NG-Nitroarginine Methyl Ester-Induced Preeclampsia With Fetal Growth Restriction-Like Symptoms in Pregnant Mice Am J Hypertens. 2017 Dec 8;31(1):89-96.
5. 村阪敏規, 池村健治, 榎屋友幸, 他. 残薬に対する住民の意識向上を目指した講演会の効果 日本薬剤師会雑誌 2017;69(10):1279-1283.
6. Muraki Y, Mizuno S, Nakatani K, et al. Monitoring of peripheral blood cluster of differentiation 4 + adenosine triphosphate activity and CYP3A5 genotype to determine the pharmacokinetics, clinical effects and complications of tacrolimus in patients with autoimmune diseases Exp Ther Med. 2018 Jan;15(1):532-538.
7. Enokiya T, Nishikawa K, Muraki Y, et al. Usefulness of limited sampling strategy for mycophenolic acid area under the curve considering postoperative days in living-donor renal transplant recipients with concomitant prolonged-release tacrolimus J Pharm Health Care Sci. 2017 Jun 24;3:17
8. Iwamoto T, Morikawa T, Hioki M, et al. Performance evaluation of the compounding robot, APOTECAchemo, for injectable anticancer drugs in a Japanese hospital J Pharm Health Care Sci. 2017 Jun 24;3:17.
9. Ikemura K, Oshima K, Enokiya T, et al. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study Cancer Chemother Pharmacol. 2017 May;79(5):943-949.
